Giverny Capital Asset Management, LLC released its Q3 2025 investor letter, showing a 6.78% return in the quarter and 12.57% YTD, compared to the S&P 500’s 8.12% and 14.83%. The fund’s top 5 holdings for 2025 are highlighted in the letter for review.

Medpace Holdings, Inc. (NASDAQ:MEDP) was featured in Giverny Capital Asset Management’s Q3 2025 investor letter. The clinical research-based drug and medical device development services provider saw a one-month return of -8.89% and shares gained 60.60% over the last 52 weeks, closing at $549.17 per share on December 08, 2025.

Giverny Capital Asset Management expressed confidence in Medpace Holdings, Inc. (NASDAQ:MEDP) in its Q3 2025 investor letter, citing the company’s strengths in clinical trials for early-stage biopharmaceutical companies. Although not among the 30 most popular stocks among hedge funds, Medpace Holdings, Inc. reported a 23.7% year-over-year revenue increase in Q3 2025.

In another article, Madison Mid Cap Fund shared views on Medpace Holdings, Inc. (NASDAQ:MEDP). For more investor letters and insights from hedge funds, visit the hedge fund investor letters Q3 2025 page on Insider Monkey. For more stock analysis, see “The Best and Worst Dow Stocks for the Next 12 Months” and “10 Unstoppable Stocks That Could Double Your Money.”

No promotional or marketing information is included in these summaries.

Read more at Yahoo Finance: What Makes Medpace Holdings (MEDP) an Investment Choice?